fda warning bpc-157 safety concerns Regulatory Alert: FDA's April 2026 Update on and GHK-Cu – Holt Law FDA's Overreach on Compounded Peptides
Description
Time will tell, and we will monitor the landscape and provide recommendations as the picture continues to develop
Purpose: It is used to reconstitute dry (lyophilized) drugs or dilute concentrated injectable drugs according to the drug manufacturers instructions
The best outcome from July's meeting is not simply "yes" or "no" on compounding eligibility it is a regulatory posture that treats these compounds with the scientific rigor their biological plausibility warrants
The current FDA roster, updated December 1, 2025, lists the chair as vacant and shows three active voting members: Timothy D
